Drug Profile
Navacaprant - Neumora Therapeutics
Alternative Names: BTRX-140; BTRX-335140; CYM-53093; Navacaprant; NMRA-140; NMRA-335140Latest Information Update: 12 Jan 2024
Price :
$50
*
At a glance
- Originator BlackThorn Therapeutics
- Developer Neumora Therapeutics
- Class Amines; Antidepressants; Anxiolytics; Behavioural disorder therapies; Fluorinated hydrocarbons; Mood stabilisers; Oxadiazoles; Piperidines; Quinolines; Small molecules
- Mechanism of Action Opioid kappa receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
Most Recent Events
- 21 Dec 2023 Neumora Therapeutics initiates a phase III KOASTAL-3 trial for Major depressive disorder (MDD) in USA (PO) (NCT06058039)
- 20 Dec 2023 Neumora Therapeutics initiates a phase III KOASTAL-2 trial for Major depressive disorder (MDD) in USA (PO) (NCT06058013)
- 10 Nov 2023 Neumora Therapeutics initiates a phase III KOASTAL-LT trial for Major depressive disorder in USA (PO) (NCT06029439)